
    
      Eligible participants for this study must have a diagnosis of probable Alzheimer's disease
      (AD) and must have clinically significant, moderate/severe agitation secondary to AD.

      This is a multicenter, randomized, double-blind, placebo-controlled, parallel-design study,
      consisting of 12 weeks of treatment.

      Approximately 550 participants will be enrolled at approximately 90 centers worldwide.

      Study medication will be administered orally twice-daily from Day 1 through Day 85. Screening
      will occur within approximately 4 weeks prior to randomization. Following screening
      procedures for assessment of inclusion and exclusion criteria, eligible participants will be
      randomized into the study.
    
  